Author Correction to: Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson's Disease
- PMID: 29637528
- PMCID: PMC6828147
- DOI: 10.1007/s40263-018-0510-z
Author Correction to: Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson's Disease
Abstract
An Online First version of this article was made available online at http://link.springer.com/journal/40263/onlineFirst/page/1 on 12 March 2018. An error was subsequently identified in the article, and the following correction should be noted.
Erratum for
-
Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson's Disease.CNS Drugs. 2018 Apr;32(4):387-398. doi: 10.1007/s40263-018-0498-4. CNS Drugs. 2018. PMID: 29532440 Free PMC article. Clinical Trial.
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
